Ultragenyx Pharmaceutical

RAREleader

Ultragenyx is a rare-disease biopharmaceutical company with multiple approved therapies and a gene therapy pipeline, focusing on metabolic and bone diseases with no or limited treatment options.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($652M)

Datos estáticos (cargando finanzas en tiempo real…)

Crysvita Royalties + Direct (60%)

Other Products (40%)

Composición de segmentos y clientes principales

Detalles del producto

Mepsevii (MPS VII)18%

IV enzyme replacement therapy for mucopolysaccharidosis VII — ultra-rare metabolic disorder.

Crysvita (XLH / TIO)45%

Burosumab monoclonal antibody for X-linked hypophosphatemia, the most common inherited form of rickets.

GTX-102 / setrusumab (bone diseases)15%

Gene therapy pipeline targeting osteogenesis imperfecta (brittle bone disease) and related disorders.

UX111 / delandistrogene (UCD, other)22%

AAV gene therapy programs for rare liver-based metabolic disorders and DMD.

Relaciones en la Cadena de Suministro

Socios

kyowa

Crysvita (burosumab) co-development

Impacto: critical

Contexto macro y de mercado

헬스케어Noticias del sector

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Próximos catalizadores

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Ultragenyx Pharmaceutical impulsado por IA.

Información de la Empresa

Sede Central

Novato, California, USA

Fundación

2010

Empleados

1,200

Sitio Web

ultragenyx.com

Estado del sector — 헬스케어

Noticias del sector